Nu Skin Enterprises, Inc. Common Stock (NUS)
Industrials › Wholesale-Drugs, Proprietaries & Druggists' Sundries
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- Trading 82% below Graham Number ($33.44) — significant margin of safety
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 18.6% — good return on equity
- Revenue declining 14% annually
Nu Skin Enterprises, Inc. Common Stock (NUS) is a Industrials company operating in Wholesale-Drugs, Proprietaries & Druggists' Sundries, listed on the NYSE , with a market capitalisation of $288 million . Key value metrics: P/E ratio 2.0, P/B ratio 0.36, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Nu Skin Enterprises, Inc. Common Stock — Fundamental Analysis Summary
Nu Skin Enterprises, Inc. Common Stock (NUS) is trading 82% below its Graham Number of $33.44 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.0x.
On financial health, NUS shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and solid return on equity of 18.6% (sector average: 4.9%), and minimal leverage with a debt-to-equity ratio of 0.26.
StockPik's composite Value Score for NUS is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NUS reports a high gross margin of 68.5% (sector average: 46.3%) and a modest operating margin of 3.2%.
NUS shows revenue declining at 14% year-over-year, with earnings growing at 209%.